US › Healthcare

Relmada Therapeutics Inc (RLMD)

US · Healthcare · Biotechnology

$4.20-0.47%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-12.9M

EPS

$-0.11

EPS estimate

$-0.21

EPS came in at -0.11 against a street estimate of -0.21 — a beat of 47.6%.

Key statistics

Market cap

$450.1M

Forward P/E

0.0

P/B

2.30

Book value

$10.15

EPS (TTM)

$-0.91

52-week high

$8.00

52-week low

$1.47

50-day MA

$5.03

200-day MA

$5.48

Beta

0.45

Analyst view

Analysts rate Relmada Therapeutics Inc a hold (0 buy, 3 hold, 0 sell out of 3) with an average price target of $12.40.

Shareholding

Insiders

2.85%

Institutions

94.60%

Largest institutional holders

Fund	Stake
HHG PLC	10.37%
Squadron Capital Management LLC	6.89%
Spruce Street Capital LP	5.99%
VR Adviser, LLC	4.54%
Adage Capital Partners Gp LLC	4.47%
Orbimed Advisors LLC	4.42%
Marshall Wace Asset Management Ltd	4.20%
Jones Hill Capital LP	3.43%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Relmada Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.